Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)
China · Delayed Price · Currency is CNY 67.03
0.00 (0.00%)
At close: May 6, 2026
SHA:688710 Revenue
Shanghai InnoStar Bio-tech had revenue of 210.08M CNY in the quarter ending March 31, 2026, with 0.43% growth. This brings the company's revenue in the last twelve months to 812.23M, down -22.99% year-over-year. In the year 2025, Shanghai InnoStar Bio-tech had annual revenue of 811.33M, down -28.94%.
Revenue (ttm)
812.23M
Revenue Growth
-22.99%
P/S Ratio
11.63
Revenue / Employee
748.60K
Employees
1,092
Market Cap
9.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 811.33M | -330.34M | -28.94% |
| Dec 31, 2024 | 1.14B | 103.24M | 9.94% |
| Dec 31, 2023 | 1.04B | 175.36M | 20.32% |
| Dec 31, 2022 | 863.07M | 281.30M | 48.35% |
| Dec 31, 2021 | 581.77M | 248.00M | 74.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.56B |
| Zhejiang Int'l Group | 33.84B |
| Yifan Pharmaceutical | 5.06B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.11B |
| GuangYuYuan Chinese Herbal Medicine | 1.44B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.09B |
| Hangzhou Minsheng Healthcare | 827.65M |
| Chongqing Lummy Pharmaceutical | 759.50M |